Organization
Oxford BioTherapeutics
1 clinical trial
Clinical trial
A Phase I, Open-label, Dose Finding Study to Assess the Safety, Tolerability, PK, and Preliminary Efficacy of OBT076, a CD205-directed ADC, in Recurrent and/or Metastatic CD205+ Solid TumorsStatus: Recruiting, Estimated PCD: 2026-12-31